4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Sell
19
SYRE Quote, Financials, Valuation and Earnings
Last price:
$22.45
Seasonality move
:
13.64%
Day range:
$21.60 - $23.76
52-week range:
$20.07 - $47.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
771.72x
P/B ratio:
7.69x
Volume:
686.8K
Avg. volume:
505.6K
1-year change:
1.49%
Market cap:
$1.3B
Revenue:
$886K
EPS (TTM):
-$4.12
Analysts' Opinion
-
Consensus RatingSpyre Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $43.14, Spyre Therapeutics has an estimated upside of 161.02% from its current price of $22.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.00 representing 100% downside risk from its current price of $22.46.
Fair Value
-
According to the consensus of 11 analysts, Spyre Therapeutics has 161.02% upside to fair value with a price target of $43.14 per share.
SYRE vs. S&P 500
-
Over the past 5 trading days, Spyre Therapeutics has underperformed the S&P 500 by -3.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Spyre Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Spyre Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Spyre Therapeutics reported revenues of --.
Earnings Growth
-
Spyre Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Spyre Therapeutics reported earnings per share of -$1.06.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
771.72x
EV / EBIT:
--
EV / Revenue:
863.30x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-7.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5.8M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$86.1M | -$100M | -$195.1M | -$33.2M | -$55.4M | |
| EBITDA | -$84.2M | -$98.9M | -$195.1M | -$33.2M | -$55.4M | |
| Diluted EPS | -$28.61 | -$50.58 | -$4.12 | -$0.86 | -$1.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $144.4M | $117.5M | $82.2M | $205.9M | $421.1M | |
| Total Assets | $155.6M | $129.1M | $91.6M | $207.3M | $421.1M | |
| Current Liabilities | $14.3M | $20.4M | $17.7M | $44.9M | $57.5M | |
| Total Liabilities | $19.4M | $27M | $24M | $452.7M | $93.7M | |
| Total Equity | $136.3M | $102.1M | $67.6M | -$245.4M | $327.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$81.3M | -$87M | -$151.2M | -$34.6M | -$29.4M | |
| Cash From Investing | $52.7M | -$59.1M | -$218M | -$97.6M | $42.7M | |
| Cash From Financing | $42.8M | $197.5M | $348.9M | -$12.5M | $12.8M | |
| Free Cash Flow | -$81.3M | -$87M | -$151.2M | -$34.6M | -$29.4M | |
SYRE
Sector
Market Cap
$1.3B
$47.5M
Price % of 52-Week High
46.82%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
1.49%
-34.04%
Beta (5-Year)
2.860
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$23.66
200-day SMA
Sell
Level
$30.20
Bollinger Bands (100)
Sell
Level
24.85 - 32.47
Chaikin Money Flow
Sell
Level
-237.8M
20-day SMA
Sell
Level
$23.91
Relative Strength Index (RSI14)
Sell
Level
35.95
ADX Line
Sell
Level
35.03
Williams %R
Buy
Level
-80.4989
50-day SMA
Sell
Level
$28.11
MACD (12, 26)
Sell
Level
-1.08
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
342.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.3702)
Sell
CA Score
(Annual)
Level (-2.9616)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.007)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Stock Forecast FAQ
In the current month, SYRE has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SYRE average analyst price target in the past 3 months is $43.14.
-
Where Will Spyre Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Spyre Therapeutics share price will rise to $43.14 per share over the next 12 months.
-
What Do Analysts Say About Spyre Therapeutics?
Analysts are divided on their view about Spyre Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Spyre Therapeutics is a Sell and believe this share price will drop from its current level to $31.00.
-
What Is Spyre Therapeutics's Price Target?
The price target for Spyre Therapeutics over the next 1-year time period is forecast to be $43.14 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SYRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Spyre Therapeutics is a Buy. 10 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SYRE?
You can purchase shares of Spyre Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Spyre Therapeutics shares.
-
What Is The Spyre Therapeutics Share Price Today?
Spyre Therapeutics was last trading at $22.45 per share. This represents the most recent stock quote for Spyre Therapeutics. Yesterday, Spyre Therapeutics closed at $22.46 per share.
-
How To Buy Spyre Therapeutics Stock Online?
In order to purchase Spyre Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
